New Ingrezza Data Shows Improved Quality of Life and Daily Functioning in Tardive Dyskinesia

New study results show Ingrezza (valbenazine) for tardive dyskinesia (TD ) improved patient-reported quality of life and functionality, as well as movement severity.¹ The phase 4 open-label KINECT-PRO study found improvement in TD symptoms and quality of life with Ingrezza, regardless of underlying psychiatric diagnosis or baseline movement severity.²

"The KINECT-PRO clinical study incorporated validated patient-reported measures, including the Tardive Dyskinesia Impact Scale (TDIS), to better understand the effects of treating tardive dyskinesia with Ingrezza on patient-reported quality of life and functioning," said Sanjay Keswani, MD, chief medical officer of Neurocrine Biosciences. "These findings add to the extensive body of evidence supporting the meaningful improvements Ingrezza has on movement severity and quality of life and functionality."

KINECT-PRO measured primary endpoints of change from baseline to week 24 in TDIS, EuroQoL Visual Analogue Scale, and Sheehan Disability Scale. Secondary endpoints included clinician and patient reported changes in TD severity on the Abnormal Involuntary Movement Scale, Patient Global Impression of Change, and Clinical Global Impression of Severity-TD. The study enrolled 59 patients who received Ingrezza (40 mg, 60 mg, or 80 mg) once daily for up to 24 weeks. Baseline measurements showed approximately 41% of patients had mild TD movement severity and approximately 59% had moderate or severe movement severity. About 46% of participants had a diagnosis of schizophrenia or schizoaffective disorder, and about 54% had diagnosed major depressive disorder or bipolar disorder. Of the 59 total participants, 52 completed the final week 24 visit.

Approximately 58% of patients met the threshold for symptomatic remission of TD, according to clinician assessment of movement severity. Overall mean improvements in patient-reported impacts of TD and movement severity exceeded thresholds for clinically meaningful change as early as week 8 and week 4, sustained at week 24. Improvement was seen regardless of underlying psychiatric diagnosis or initial TD movement severity. Patients with milder TD movement severity experienced clinically meaningful improvement, with a -6.8 mean change in TDIS and -5.6 mean change in AIMS. Safety and tolerability of Ingrezza were consistent with the known profile, and no new concerns were identified.

"Quality of life and day-to-day functioning are important considerations when evaluating the impact of tardive dyskinesia and treatment goals," said Christoph U. Correll, MD, primary author of the manuscript. "These findings showed improvements with Ingrezza in both clinician-rated movement severity and patient-reported daily impact and reinforced the potential for meaningful benefit across a broad range of patients regardless of baseline movement severity or underlying psychiatric diagnosis," he added.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of tardive dyskinesia in adults. The medication selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic, serotonergic, adrenergic, histaminergic, or muscarinic receptors. It is taken as a capsule once daily, and is combinable with most stable regiments like antipsychotics and antidepressants. Ingrezza is also available in a sprinkle formulation for patients experiencing dysphagia or preferring a non-pill form.

References

1. Neurocrine Biosciences announces publication of KINECT-PRO findings demonstrating Ingrezza (valbenazine) capsules improved patient-reported quality of life and daily functioning for people living with tardive dyskinesia. Press release. August 12, 2026. Accessed August 12, 2026. https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-kinect-pro-findings-demonstrating-ingrezza-valbenazine-capsules-improved-patient-reported-quality-of-life-and-daily-functioning-for-people-living-with-tardive-dyskinesia-302848825.html

2. Correll CU, Perez-Rodriguez M, McEvoy JP, et al. Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO study. CNS Spect. 2026.